Merck KGaA announced in December the top-line results of its failed phase III trials of evobrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, but few details were available at that time. Full results have now been presented by Dr. Xavier Montalban, Barcelona, Spain, at the ACTRIMS Forum conference, held February 29-March 2 in West Palm Beach, Florida. Read More
Latest News
New consensus statement on MRI biomarkers in MS
February 20, 2024The North American Imaging in Multiple Sclerosis (NAIMS) cooperative has issued a consensus statement on chronic active lesions (CAL) in MS and how biomarkers may be employed to evaluate them (Bagnato et al. Brain 2024; epublished January 16, 2024). Read More
No benefit with adjuvant vitamin D in MS: meta-analysis
February 12, 2024A new meta-analysis (9 studies, N=867) has concluded that high-dose vitamin D3 supplementation does not have a significant impact on clinical outcomes in patients with MS (Mahler et al. Mult Scler Relat Disord 2024:82:105433). Read More
McDonald criteria 2024: what changes can we expect?
January 30, 2024The International Advisory Committee on Clinical Trials in MS convened in Barcelona on November 29 to discuss the latest round of revisions to the McDonald diagnostic criteria. The criteria were last revised in 2017 (Thompson et al. Lancet Neurol 2018;17:162-173). The in-person meeting followed a series of virtual meetings of the group in 2022 to discuss some of the issues not addressed in the 2017 criteria, such as the role of the visual system in diagnosis, the use of high-field MRI and which biomarkers can be used to support an MS diagnosis. Read More